Prosthesis Versus Active Exercise Program in Patients With Glenohumeral Osteoarthritis (PROACT)
Primary Purpose
Glenohumeral Osteoarthritis
Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
TSA-group
Exercise-group
Sponsored by
About this trial
This is an interventional treatment trial for Glenohumeral Osteoarthritis focused on measuring Physiotherapist-supervised Exercise, Physical Therapy, Physical Rehabilitation, Anatomical total shoulder arthroplasty, Randomized Controlled Trial
Eligibility Criteria
Inclusion Criteria:
- Patients ≥55-85 years
- Moderate-severe primary OA of the glenohumeral joint according to Samilson and Prieto, by measuring the lower osteophyte (32)
- Eligible for surgery with standard TSA
Exclusion Criteria:
- Surgical need for bonegraft
- Previous shoulder fracture (fracture of the proximal humerus or glenoid fracture)
- Planned other upper extremity surgery within six months
- Rheumatoid arthritis or other types of arthritis not diagnosed as primary glenohumeral OA
- Cancer diagnosis and receiving chemo-, immuno- or radiotherapy
- Neurological diseases affecting shoulder mobility (e.g. disability after previous stroke, multiple sclerosis, Parkinson's, Alzheimer's disease)
- Other reasons for exclusion (i.e. mentally unable to participate) or planned absence for more than 14 days in the first 3 months after baseline test.
- Unable to communicate in the participating countries respective languages
Sites / Locations
- Aarhus University HospitalRecruiting
- Aalborg University HospitalRecruiting
- Silkeborg Regional HospitalRecruiting
- Viborg Regional HospitalRecruiting
- Tampere University Hospital
- Oslo University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
TSA-group
Exercise-group
Arm Description
Surgery
Exercise
Outcomes
Primary Outcome Measures
the Western Ontario Osteoarthritis of the Shoulder index (WOOS)
WOOS consist of 19 items to be answered using a visual analog scale (VAS). Each item has a possible score ranging from 0 to 100, leading to a total WOOS score ranging from 0 to 1900, with 0 being the best. For simplicity reasons, raw scores can be converted to a percentage of the maximum score (0-100, 100 best).
Secondary Outcome Measures
the Western Ontario Osteoarthritis of the Shoulder index (WOOS)
WOOS consist of 19 items to be answered using a visual analog scale (VAS). Each item has a possible score ranging from 0 to 100, leading to a total WOOS score ranging from 0 to 1900, with 0 being the best. For simplicity reasons, raw scores can be converted to a percentage of the maximum score (0-100, 100 best).
Disabilities of the Arm, Shoulder and Hand (DASH)
DASH is a self-administered questionnaire that consist of thirty core items and eight items assessing work and sports and/or performing arts activities. Each individual item is scored on a 5-point Likert scale, and lower scores correlated to minimal impairments and higher scores indicate more impairment. The cumulative DASH score is scaled from 0-100 with higher scores indicating more disability.
The 100 mm Visual Analogue Scale.
Patient reported pain intensity at rest, during activity and nightly pain.
The use of analgesics during the last week
They will be asked if they take any analgesics, which type they take (paracetamol, NSAID, morphine/opioids) and how often they consume the medication.
Serious Adverse Events
Serious adverse events are defined as embolism (cardiac or brain), death, liver and renal failure.
Adverse events
Defined as any unintended and unfavorable sign, symptom or disease resulting in contact with the healthcare system irrespective of a causal relationship with the intervention and outcome assessments.
Full Information
NCT ID
NCT04845074
First Posted
April 13, 2021
Last Updated
May 9, 2023
Sponsor
University of Aarhus
Collaborators
Aarhus University Hospital, Tampere University Hospital, Regionshospitalet Viborg, Skive, Aalborg University Hospital, Regionshospitalet Silkeborg, Oslo University Hospital, The Danish Rheumatism Association, Association of Danish Physiotherapists
1. Study Identification
Unique Protocol Identification Number
NCT04845074
Brief Title
Prosthesis Versus Active Exercise Program in Patients With Glenohumeral Osteoarthritis
Acronym
PROACT
Official Title
Prosthesis Versus Active Exercise Program in Patients With Glenohumeral Osteoarthritis Eligible For Shoulder Arthroplasty: the ProAct Multicenter, Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 2, 2021 (Actual)
Primary Completion Date
November 2025 (Anticipated)
Study Completion Date
November 2035 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Aarhus
Collaborators
Aarhus University Hospital, Tampere University Hospital, Regionshospitalet Viborg, Skive, Aalborg University Hospital, Regionshospitalet Silkeborg, Oslo University Hospital, The Danish Rheumatism Association, Association of Danish Physiotherapists
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Anatomical total shoulder arthroplasty (TSA) is a well-established treatment for pronounced glenohumeral osteoarthritis. However, the effectiveness of TSA has not been compared to non-surgical treatment in a randomised controlled trial. Shoulder exercises may be an effective treatment for reducing pain and improving function in glenohumeral osteoarthritis. The primary aim of this trial is to examine if TSA followed by standard postsurgical rehabilitation is superior to a 12-week exercise programme in patients with primary glenohumeral OA eligible for unilateral TSA. We hypothesise that surgical intervention followed by standard rehabilitation, results in clinically relevant (18-point, on a scale from 0-100) improvement compared to the exercise intervention.
Detailed Description
Glenohumeral osteoarthritis causes pain, stiffness and weakness in the shoulder joint, and furthermore, it affects activities of daily living and quality of life. Anatomical total shoulder arthroplasty (TSA) is a well-established treatment for pronounced glenohumeral osteoarthritis. Several studies have suggested the need for trials comparing shoulder arthroplasty to non-surgical treatments.
The ProAct trial is a Nordic multicenter randomized controlled trial. Patients with glenohumeral osteoarthritis, eligible for a TSA will be randomised to either TSA followed by usual care or exercise only. The exercise intervention consists of 12 weeks of exercise with one weekly physiotherapist-supervised exercise session.
The primary outcome will be the total the Western Ontario Osteoarthritis of the Shoulder index score at 12 months follow-up.Outcome assessment will be performed at baseline, and at 3 and 12 months and 2-, 5- and 10 years after start of surgical/non-surgical treatment.
Patients fulfilling the eligibility criteria but declining to participate in the randomised trial will be offered the option of participating in an observational cohort using the same primary end point and patient reported outcomes, but following usual clinical practice.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Glenohumeral Osteoarthritis
Keywords
Physiotherapist-supervised Exercise, Physical Therapy, Physical Rehabilitation, Anatomical total shoulder arthroplasty, Randomized Controlled Trial
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
102 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
TSA-group
Arm Type
Experimental
Arm Description
Surgery
Arm Title
Exercise-group
Arm Type
Experimental
Arm Description
Exercise
Intervention Type
Procedure
Intervention Name(s)
TSA-group
Intervention Description
Anatomical total shoulder arthroplasty followed by standard rehabilitation.
Intervention Type
Other
Intervention Name(s)
Exercise-group
Intervention Description
The exercise-group will attend a 12-week exercise program with one weekly physiotherapist-supervised session supplemented with two weekly sessions of home-based exercises. Utilisation of a predefined training protocol describing procedures and content of each session secure uniformity and standardisation of the intervention. The exercise program consists of two warm-up exercises and five exercises that target shoulder range of motion and muscle strength. Furthermore, a link to a video, informing about glenohumeral osteoarthritis, the role of exercise and exercise related pain, will be sent to all patients in the exercise-group. The physiotherapists delivering the exercise intervention are not otherwise related to the trial.
Primary Outcome Measure Information:
Title
the Western Ontario Osteoarthritis of the Shoulder index (WOOS)
Description
WOOS consist of 19 items to be answered using a visual analog scale (VAS). Each item has a possible score ranging from 0 to 100, leading to a total WOOS score ranging from 0 to 1900, with 0 being the best. For simplicity reasons, raw scores can be converted to a percentage of the maximum score (0-100, 100 best).
Time Frame
Measured at 12-month follow-up
Secondary Outcome Measure Information:
Title
the Western Ontario Osteoarthritis of the Shoulder index (WOOS)
Description
WOOS consist of 19 items to be answered using a visual analog scale (VAS). Each item has a possible score ranging from 0 to 100, leading to a total WOOS score ranging from 0 to 1900, with 0 being the best. For simplicity reasons, raw scores can be converted to a percentage of the maximum score (0-100, 100 best).
Time Frame
Measured at baseline, 12-week, 2-, 5- and 10-year follow-up
Title
Disabilities of the Arm, Shoulder and Hand (DASH)
Description
DASH is a self-administered questionnaire that consist of thirty core items and eight items assessing work and sports and/or performing arts activities. Each individual item is scored on a 5-point Likert scale, and lower scores correlated to minimal impairments and higher scores indicate more impairment. The cumulative DASH score is scaled from 0-100 with higher scores indicating more disability.
Time Frame
Measured at baseline, 12-week, 12-month, 2-, 5- and 10-year follow-up
Title
The 100 mm Visual Analogue Scale.
Description
Patient reported pain intensity at rest, during activity and nightly pain.
Time Frame
Measured at baseline, 12-week, 12-month, 2-, 5- and 10-year follow-up
Title
The use of analgesics during the last week
Description
They will be asked if they take any analgesics, which type they take (paracetamol, NSAID, morphine/opioids) and how often they consume the medication.
Time Frame
Measured at baseline, 12-week, 12-month, 2-, 5- and 10-year follow-up
Title
Serious Adverse Events
Description
Serious adverse events are defined as embolism (cardiac or brain), death, liver and renal failure.
Time Frame
The patients in the surgical intervention group will be monitored for serious adverse events during the 4 weeks from the discharge.
Title
Adverse events
Description
Defined as any unintended and unfavorable sign, symptom or disease resulting in contact with the healthcare system irrespective of a causal relationship with the intervention and outcome assessments.
Time Frame
Occurring during the period from inclusion until the 12-month follow-up
Other Pre-specified Outcome Measures:
Title
Accelerometer-based activity using tri-axial (Axivity, UK) accelerometers
Description
The patients will have an accelerometer sensor mounted with tape to both upper arms for 4 days. The sensors will measure 24/7 activity and degree of movement.
Time Frame
Measured at baseline and 12-month follow-up
Title
The 100 mm Visual Analogue Scale.
Description
Patient reported pain intensity at rest
Time Frame
Measured immediately before and after each exercise session
Title
EQ-5D-5L
Description
The EuroQol measures the five dimensions: mobility, self-care, daily activities, pain/discomfort, and anxiety/depression. Each dimension consists of one item, distinguished in five levels.
Time Frame
Measured at baseline, 12-week, 12-month, 2-, 5- and 10-year follow-up.
Title
Productivity Costs Questionnaire (iPCQ)
Description
The iPCQ is a questionnaire for the measurement of costs in economic evaluations. It consists of 18 questions of which 9 are general questions followed by questions to measure productivity losses. Measured for the health economic evaluation in Denmark.
Time Frame
Measured at 12-week, 12-month follow-up.
Title
Patient Acceptable Symptom State (PASS)
Description
PASS will be assessed with the following question: "When you think of your shoulder function, will you consider your current condition as satisfying?" By shoulder function, you should take into account your activities of daily living, sport and recreational activities, your shoulder pain and other symptoms and your quality-of-life on a dichotomous scale (yes/no).
Time Frame
Measured at 12-month, 2-, 5- and 10-year follow-up.
Title
Treatment Failure
Description
Patient-reported treatment failure will be assessed only by patients answering "no" to PASS with the following question: "Would you consider your current state as being so unsatisfactory that you think the treatment has failed?" on a dichotomous scale (yes/no).
Time Frame
Measured at 12-month, 2-, 5- and 10-year follow-up.
Title
Number of total shoulder arthroplasty surgeries (exercise-group)
Description
Number of total shoulder arthroplasty surgeries performed in the exercise-group.
Time Frame
Measured from baseline to 12-month, 2-, 5- and 10-year follow-up.
Title
Number of supervised exercise sessions from baseline to 3 months (exercise-group)
Description
High compliance will be defined as participation in ≥70% of the training sessions; moderate compliance as participation in 50-70% of the sessions; and poor compliance as participation in <50% of the sessions.
Time Frame
From baseline to 12 weeks
Title
Number of patients performing unsupervised exercise (exercise-group)
Description
Adherence to two weekly unsupervised exercise sessions will be measured by a patient-reported questionnaire
Time Frame
From baseline to 12 weeks
Title
Number of patients performing unsupervised exercise (exercise-group)
Description
Adherence to optional unsupervised exercise sessions will be measured by a patient-reported questionnaire
Time Frame
From 12 weeks to 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
55 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients ≥55-85 years
Moderate-severe primary OA of the glenohumeral joint according to Samilson and Prieto, by measuring the lower osteophyte (32)
Eligible for surgery with standard TSA
Exclusion Criteria:
Surgical need for bonegraft
Previous shoulder fracture (fracture of the proximal humerus or glenoid fracture)
Planned other upper extremity surgery within six months
Rheumatoid arthritis or other types of arthritis not diagnosed as primary glenohumeral OA
Cancer diagnosis and receiving chemo-, immuno- or radiotherapy
Neurological diseases affecting shoulder mobility (e.g. disability after previous stroke, multiple sclerosis, Parkinson's, Alzheimer's disease)
Other reasons for exclusion (i.e. mentally unable to participate) or planned absence for more than 14 days in the first 3 months after baseline test.
Unable to communicate in the participating countries respective languages
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Josefine B. Larsen, MSc
Phone
+4526237771
Email
josefinebl@clin.au.dk
First Name & Middle Initial & Last Name or Official Title & Degree
Inger Mechlenburg, Prof.
Phone
+4521679062
Email
inger.mechlenburg@clin.au.dk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Josefine B. Larsen, MSc
Organizational Affiliation
Aarhus University Hospital and Aarhus University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Inger Mechlenburg, Prof.
Organizational Affiliation
Aarhus University Hospital and Aarhus University
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Theis M. Thillemann, PhD, As Prof
Organizational Affiliation
Aarhus University Hospital and Aarhus University
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Antti P. Launonen, PhD, As Prof
Organizational Affiliation
Tampere University Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Aarhus University Hospital
City
Aarhus
ZIP/Postal Code
8200
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Josefine Larsen, Msc
Email
josefinebl@clin.au.dk
First Name & Middle Initial & Last Name & Degree
Inger Mechlenburg, Prof.
Email
inger.mechlenburg@clin.au.dk
First Name & Middle Initial & Last Name & Degree
Theis M Thillemann, PhD, As Prof
Facility Name
Aalborg University Hospital
City
Farsø
ZIP/Postal Code
9640
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Steen L Jensen
Facility Name
Silkeborg Regional Hospital
City
Silkeborg
ZIP/Postal Code
8600
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Brian Elmegaard
First Name & Middle Initial & Last Name & Degree
Stine J Due
Facility Name
Viborg Regional Hospital
City
Viborg
ZIP/Postal Code
8800
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Helle K Østergaard
First Name & Middle Initial & Last Name & Degree
Srdjan Zivanovic
Facility Name
Tampere University Hospital
City
Tampere
ZIP/Postal Code
33521
Country
Finland
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antti P. Launonen, PhD, As Prof
Email
antti.launonen@pshp.fi
Facility Name
Oslo University Hospital
City
Oslo
ZIP/Postal Code
4956
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Berte Bøe
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Pseudo anonymised patient-level data for the primary and all secondary outcome measures will be made available if required by the scientific journal, in which the results of the trial are published.
IPD Sharing Time Frame
Data will be available after publication of the trial.
IPD Sharing Access Criteria
Data access will be reviewed by the author group. Requestors will be required to sign a Data Access Agreement.
Citations:
PubMed Identifier
35138410
Citation
Beck Larsen J, Thillemann TM, Launonen AP, Ostergaard HK, Falstie-Jensen T, Reito A, Lund Jensen S, Mechlenburg I. Study protocol: Prosthesis versus Active (ProAct) exercise program in patients with glenohumeral osteoarthritis - a multicenter, randomized controlled trial. Acta Orthop. 2022 Feb 8;93:303-316. doi: 10.2340/17453674.2022.2043.
Results Reference
derived
Learn more about this trial
Prosthesis Versus Active Exercise Program in Patients With Glenohumeral Osteoarthritis
We'll reach out to this number within 24 hrs